Kindeva Opens New UK HQ & Manufacturing Site for the Development of Next-Generation Propellants
Kindeva, a global CDMO and drug delivery expert, has officially opened its new UK headquarters at Charnwood Campus Science Innovation and Technology Park, Loughborough. The facility represents a significant expansion in Kindeva’s MDI services and will develop and test next-generation propellants (NGP) as the industry prepares to move to more environmentally friendly products.
Nestled in the heart of Loughborough’s Technology Park, the 150,000 sq. ft. site offers a range of services across drug development, from early-stage viability, analytical method development, to commercial analysis. Boasting a Chemistry, Manufacturing and Controls (CMC) strategy and regulatory department to guide customers through complex compliance hurdles, the facility will support customers at every stage of the drug development journey.
The official opening will be marked with a launch event hosted by the CEO of Kindeva, Milton Boyer and David Northage, Mayor of Charnwood. A ribbon-cutting ceremony will be followed by a site tour, where Kindeva will unveil its investment and recruitment strategy for the future.
Commenting on the new site, Milton Boyer said “The opening of our Loughborough Headquarters marks a significant milestone in Kindeva’s growth strategy as we continue to innovate, scale, and expand our global footprint.”
The Loughborough HQ will be responsible for developing and analysing NGPs as the industry faces significant legislation aimed at reducing the environmental impact of the propellants currently used in pressurized metered-dose inhalers (pMDIs).
Boyer continued: “Research estimates that inhalers contribute to 0.03% of total global greenhouse gas emissions, and represent 3% of the U.K. National Health Service (NHS) carbon footprint. Investment in our Loughborough site, new technologies and people, will allow Kindeva to become the leading force in the industry for sustainability and assuring supply continuity as the industry transitions to low Global Warming Potential (GWP) propellants.”
At Kindeva, we manufacture more tomorrows for patients worldwide. With best-in-class facilities, and comprehensive CDMO services, we offer more than manufacturing – we deliver strategic value. Our global network of 10 manufacturing and testing sites offers exceptional integrated knowledge and capabilities, including Annex 1-compliant state-of-the art aseptic fill finish capacity, and next generation sustainable inhalation propellant technology. By combining expertise in injectable, pulmonary, nasal and dermal drug delivery, we help meet the demands of today and deliver the possibilities of tomorrow. www.kindevadd.com.
Total Page Views: 101
